These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of the penetration of fluoroquinolones in human conjunctival tissue. Fiscella RG, Jensen MK. Arch Ophthalmol; 2006 Dec; 124(12):1796-7; author reply 1797. PubMed ID: 17159052 [No Abstract] [Full Text] [Related]
3. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980 [Abstract] [Full Text] [Related]
4. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty. Fukuda M, Yamada M, Kinoshita S, Inatomi T, Ohashi Y, Uno T, Shimazaki J, Satake Y, Maeda N, Hori Y, Nishida K, Kubota A, Nakazawa T, Shimomura Y. Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026 [Abstract] [Full Text] [Related]
5. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798 [Abstract] [Full Text] [Related]
6. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation. Chung JL, Lim EH, Song SW, Kim BY, Lee JH, Mah FS, Seo KY. Cornea; 2013 Jul; 32(7):1046-51. PubMed ID: 23615274 [Abstract] [Full Text] [Related]
7. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty. Metallidis S, Topsis D, Nikolaidis J, Alexiadou E, Lazaraki G, Grovaris L, Theodoridou A, Nikolaidis P. J Chemother; 2007 Dec; 19(6):682-7. PubMed ID: 18230551 [Abstract] [Full Text] [Related]
8. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Yağci R, Oflu Y, Dinçel A, Kaya E, Yağci S, Bayar B, Duman S, Bozkurt A. Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216 [Abstract] [Full Text] [Related]
10. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Holland EJ, Lane SS, Kim T, Raizman M, Dunn S. Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660 [Abstract] [Full Text] [Related]
12. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. Ong-Tone L. J Cataract Refract Surg; 2008 May; 34(5):819-22. PubMed ID: 18471639 [Abstract] [Full Text] [Related]
13. Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones. Phillips ST, Nagaro K, Sambol SP, Johnson S, Gerding DN. Anaerobe; 2011 Aug; 17(4):166-9. PubMed ID: 21511046 [Abstract] [Full Text] [Related]
14. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Torkildsen G, O'Brien TP. Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788 [Abstract] [Full Text] [Related]
15. A comparison of fluoroquinolone penetration into human conjunctival tissue. Aihara M, Miyanaga M, Minami K, Miyata K, Eguchi S, Shiroma H, Sawaguchi S. J Ocul Pharmacol Ther; 2008 Dec; 24(6):587-91. PubMed ID: 19049265 [Abstract] [Full Text] [Related]
16. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244 [Abstract] [Full Text] [Related]
17. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing. Levine JM, Noecker RJ, Lane LC, Snyder RW, Rapedius M, Blanchard J. J Ocul Pharmacol Ther; 2004 Jun; 20(3):210-6. PubMed ID: 15279726 [Abstract] [Full Text] [Related]
18. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Robertson SM, Curtis MA, Schlech BA, Rusinko A, Owen GR, Dembinska O, Liao J, Dahlin DC. Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309 [Abstract] [Full Text] [Related]
19. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, Bloom A. Ophthalmology; 2005 Mar; 112(3):466-9. PubMed ID: 15745775 [Abstract] [Full Text] [Related]
20. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. Lindstrom R, Lane S, Cottingham A, Smith S, Sall K, Silverstein S, Shettle L, Walters T, Faulkner R, Cockrum P, Teuscher N. J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517 [Abstract] [Full Text] [Related] Page: [Next] [New Search]